#United States #New York #Immunic #Vidofludimus #MS

Immunic Plans Virtual R&D Event on Progressive MS

Immunic, Inc., a leading biotech firm focused on novel therapies for neurologic conditions, has announced an upcoming virtual Research and Development (R&D) Day specializing in progressive multiple sclerosis (MS). The event is scheduled for November 5, 2026, at 12:30 PM ET.

This initiative not only highlights Immunic's commitment to advancing treatment options for those affected by MS but also exemplifies its transparent communication strategy with stakeholders. During this digital gathering, key figures from Immunic's leadership team will participate, including CEO Erik Lundgren, Chief Medical Officer Michael A. Panzara, Chief Scientific Officer Hella Kohlhof, and President & COO Jason Tardio.

The R&D Day will also feature esteemed experts in the field, Dr. Jiwon Oh from the University of Toronto and Dr. Maria Pia Sormani from the University of Genoa, who will share their insights on current challenges in the management of progressive MS and the need for innovative therapeutic approaches.

A core aspect of the discussion will focus on Immunic's lead investigational drug, vidofludimus calcium (IMU-838). The company will delve into the specific unmet needs in progressive MS and present the rationale behind clinical trials aimed at exploring the efficacy of vidofludimus in treating this debilitating condition. This drug is designed to activate nuclear receptor-related 1 (Nurr1), potentially offering neuroprotective effects alongside its anti-inflammatory properties.

As part of its strategic expansion, Immunic plans to commence a Phase 3 clinical trial for vidofludimus in progressive MS later in 2026. This trial aims to validate the clinical potential of this therapeutic candidate and address the ongoing needs of MS patients who require new treatment modalities.

The upcoming virtual event promises to be an enlightening session, with discussions geared towards unveiling the innovative pathways Immunic is pursuing in the fight against multiple sclerosis. To register for this informative session, interested parties can find further details on Immunic's official website.

Immunic, Inc. has prioritised a patient-centric approach in its research endeavors. The company is determined to alleviate the burden of neurologic diseases by developing ground-breaking therapies based on comprehensive scientific principles. By highlighting the efficacy of vidofludimus calcium, it seeks to reinforce its position as a pivotal player in the biotechnology sector committed to improving the lives of those diagnosed with progressive MS.

As the event date approaches, more information will be made available, ensuring stakeholders have access to the latest findings and developments in the realm of progressive multiple sclerosis treatment. The proactive steps taken by Immunic reflect not just a corporate mission, but a genuine desire to contribute positively to the medical community's understanding and management of this complex disease.

In the ever-evolving landscape of biotechnology, Immunic stands out with its dedication to innovative research and development, shedding light on a promising path for patients suffering from neurologic disorders.

For continued updates, stakeholders and interested parties are encouraged to connect with Immunic through their online portals and media channels.